PUBLISHER: DelveInsight | PRODUCT CODE: 1381123
PUBLISHER: DelveInsight | PRODUCT CODE: 1381123
“"Regorafenib Drug Insight and Market Forecast - 2032" report provides comprehensive insights about regorafenib for glioblastoma multiforme (GBM) in the seven major markets. A detailed picture of the regorafenib for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the regorafenib for GBM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the regorafenib market forecast analysis for GBM in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in GBM.
Regorafenib is an oral multi-kinase inhibitor that potently blocks multiple protein kinases involved in tumor angiogenesis (VEGFR1, -2, -3, TIE2), oncogenesis (KIT, RET, RAF-1, BRAF), metastasis (VEGFR3, PDGFR, FGFR) and tumor immunity (CSF1R). It is an inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and pathologic processes such as oncogenesis, tumor angiogenesis, and maintenance of the tumor microenvironment.
Regorafenib is the first-choice treatment for rGBM according to Italian Association of Medical Oncology guidelines; regorafenib has been approved by Italian Medicines Agency (AIFA) for its use in rGBM as of October 2019, while bevacizumab, although approved by FDA, is not recommended by AIFA and EMA.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
This report provides a detailed market assessment of regorafenib for glioblastoma multiforme (GBM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.
The report provides the clinical trials information of regorafenib for GBM covering trial interventions, trial conditions, trial status, start and completion dates.